GTx-024

Phase 3Small molecule

GGTx

GTx-024 is one of 125 small molecule programs targeting Cachexia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

124

Competitors

Pipeline

Status by Indication[3][1]

Indication

CachexiaActive, not recruiting

Stress Urinary IncontinenceActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

CachexiaPhase 2

Active, not recruiting

Stress Urinary IncontinencePhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

GTx-024

GGTx

Phase 3

3 2

Tecentriq

Roche

Preclinical

36 3

Trodelvy

Gilead

Preclinical

37 4

Halaven

Eisai

Preclinical

38 5

Tykerb

GSK

Preclinical

80 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Stress urinary incontinence4 trials

Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence

Withdrawn·GGTx·Phase 2·NCT03508648

GTx-024 as a Treatment for Stress Urinary Incontinence in Women

Completed·GGTx·Phase 2·NCT02658448·19 enrolled

Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence

Completed·GGTx·Phase 2·NCT03241342·491 enrolled

Show 1 more trial

Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence

Withdrawn·GGTx·Phase 2·NCT03566290

Breast Cancer3 trials

Phase II Study of GTx024 in Women With Metastatic Breast Cancer

Terminated·GGTx·Phase 2·NCT01616758·22 enrolled

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

Completed·GGTx·Phase 2·NCT02463032·136 enrolled

Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

Terminated·GGTx·Phase 2·NCT02368691·32 enrolled

Non-Small Cell Lung Cancer2 trials

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

Completed·GGTx·Phase 3·NCT01355497·330 enrolled

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

Completed·GGTx·Phase 3·NCT01355484·321 enrolled

Cachexia1 trial

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

Completed·GGTx·Phase 2·NCT00467844·159 enrolled

Function1 trial

Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

Withdrawn·GGTx·Phase 2·NCT02746328

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for GTx-024. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GTx-024 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GTx-024. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GTx company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGTx

GTx-024

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Stress urinary incontinence4 trials

Breast Cancer3 trials

Non-Small Cell Lung Cancer2 trials

Cachexia1 trial

Function1 trial

References

Drug Info

Quick Facts

Related News